Rani Therapeutics: Co, Progen to Share Responsibilities for Rt-114, Including 50/50 Cost & Revenue Share
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.